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A prospective randomized study comparing fibrin
sealant to manual compression for the treatment
of anastomotic suture-hole bleeding in expanded
polytetrafluoroethylene grafts
Sibu P. Saha, MD, MBA,a Satish Muluk, MD,b Worthington Schenk, III, MD,c James W. Dennis, MD,d
Bettina Ploder, MS,e Ani Grigorian, MFA,f Isabella Presch, MD, MBA,e and
Andreas Goppelt, PhD,e Lexington, Ky; Pittsburgh, Pa; Charlottesville, Va; Jacksonville, Fla; Vienna, Austria;
and Westlake Village, Calif
Objective: The ideal hemostatic agent for treatment of suture-line bleeding at vascular anastomoses has not yet been
established. This study evaluated whether the use of a fibrin sealant containing 500 IU/mL thrombin and synthetic
aprotinin (FS; marketed in the United States under the name TISSEEL) is beneficial for treatment of challenging
suture-line bleeding at vascular anastomoses of expanded polytetrafluoroethylene (ePTFE) grafts, including those further
complicated by concomitant antiplatelet therapies.
Methods: Over a 1-year period ending in 2010, ePTFE graft prostheses, including arterio-arterial bypasses and arterio-
venous shunts, were placed in 140 patients who experienced suture-line bleeding that required treatment after
completion of anastomotic suturing. Across 24 US study sites, 70 patients were randomized and treated with FS and 70
with manual compression (control). The primary end point was the proportion of patients who achieved hemostasis at the
study suture line at 4 minutes after start of application of FS or positioning of surgical gauze pads onto the study suture line.
Results: There was a statistically significant difference in the comparison of hemostasis rates at the study suture line at 4 minutes
between FS (62.9%) and control (31.4%) patients (P< .0001), which was the primary end point. Similarly, hemostasis rates in the
subgroup of patients on antiplatelet therapies were 64.7% (FS group) and 28.2% (control group). When analyzed by bleeding
severity, the hemostatic advantage of FS over control at 4minutes was similar (27.8% absolute improvement formoderate bleeding
vs 32.8% for severe bleeding). Logistic regression analysis (accounting for gender, age, intervention type, bleeding severity, blood
pressure, heparin coatingof ePTFEgraft, and antiplatelet therapies) founda statistically significant treatment effect in theodds ratio
(OR) of meeting the primary end point between treatment groups (OR, 6.73; P< .0001), as well as statistically significant effects
for intervention type (OR, 0.25; P .0055) and bleeding severity (OR, 2.59; P .0209). The safety profile of FS was excellent as
indicated by the lack of any related serious adverse events.
Conclusions: The findings from this phase 3 study confirmed that FS is safe and its efficacy is superior to manual
compression for hemostasis in patients with peripheral vascular ePTFE grafts. The data also suggest that FS promotes
hemostasis independently of the patient’s own coagulation system, as shown in a representative population of patients
with vascular disease under single- or dual-antiplatelet therapies. ( J Vasc Surg 2012;56:134-41.)
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tExpanded polytetrafluoroethylene (ePTFE) graft place-
ment can be complicated by prolonged anastomotic suture-
hole bleeding, which increases operative time, overall blood
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134oss, and risk of wound complications.1,2 The intraopera-
ive use of heparin for prevention of thromboses and peri-
perative use of platelet inhibitors can exacerbate the prob-
em. In patients on dialysis, the underlying disease
ompromises the coagulation system and dialysis itself may
ead to increased fibrinolysis.3
Suture-hole bleeding can be managed through the use
f manual compression with surgical gauze pads, reversal of
eparin, and topical hemostatic agents. Agents such as
ollagen, oxidized cellulose, gelatin alone or in combina-
ion with thrombin,4-8 polyethylene glycol-based glues,9
elatin-resorcine-formol glues,2 and cyanoacrylate glue10
ave been used with varying success.
Fibrin sealants contain the components necessary for the
eneration of a fibrin clot and can achieve hemostasis or
ealing independently of the patient’s coagulation system.
hey have shownbeneficial resultswith respect to significantly
horter times to hemostasis than other commonly used
gents/techniques in a variety of complex clinical situa-
ions1,6-8,11-18 and with respect to significant decreases in
ortality and morbidity in spleen and liver injuries.19
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Volume 56, Number 1 Saha et al 135Our prospective controlled study evaluated the efficacy
and safety of a fibrin sealant containing 500 IU/mL throm-
bin and synthetic aprotinin (referred to herein as FS) for the
treatment of anastomotic suture-hole bleeding that is not
amenable to additional sutures during placement of ePTFE
vascular grafts.
FS is currently licensed in the United States under the
trade name TISSEEL (Baxter Healthcare Corporation,
Westlake Village, Calif). This study was part of the manu-
facturer’s clinical development program, which is aimed at
broadening the indications for FS to include hemostasis in
all surgical applications where control of bleeding by stan-
dard surgical techniques is ineffective or impractical.
METHODS
Study design. This prospective, controlled, random-
ized, subject-blinded, multicenter phase 3 study evaluated
the efficacy and safety of FS for the treatment of anasto-
motic suture-hole bleeding during ePTFE graft placement
as compared to manual compression with gauze pads, a
valid standard of care technique. The requirement for a
comparator therapy is specific to higher-risk surgical proce-
dures where hemostasis/sealing and suture support, such as
in vascular anastomoses, are critical.20-22
The study protocol was approved by the institutional
review board at each of 24 US study sites.
Patients underwent graft placement on day 0, which
was when hemostasis was assessed. Postoperative follow-up
took place at discharge or on day 1 (whichever occurred
first) and on days 14 and 30. The following surgical proce-
dures were permitted: axillofemoral, axillobifemoral, aorto-
bifemoral, iliofemoral, femorofemoral, iliopopliteal, femo-
ropopliteal, femorotibial vessel bypass, and arteriovenous
(AV) shunting for dialysis access in the upper and lower
extremities.
The primary end point was the proportion of patients
who achieved hemostasis at the study suture line of the graft
at 4 minutes after the start of either a single application of
FS or continuous manual compression with surgical gauze
pads (control) and maintained it until closure of the surgi-
cal wound. The study suture line was defined as either the
iliac or the femoral anastomosis in arterio-arterial bypasses;
the last femoral anastomosis to be completed in axillo-
bifemoral and in aortobifemoral bypasses; and the arterial
anastomoses in AV shunts. Hemostasis was defined as no
visible bleeding at the study suture line. Bleedings treated
at the nonstudy suture line were not assessed for time to
hemostasis. Patients were considered treatment failures if
hemostasis was not achieved within the first 4 minutes or
additional hemostatic treatment was administered (includ-
ing the reapplication of FS), or if intraoperative rebleeding
occurred after the first 4 minutes. This end point was
considered appropriate to detect a clinically relevant reduc-
tion of time to hemostasis in treatment groups.Secondary efficacy end points included the following: a● Proportion of patients who achieved hemostasis at the
study suture line at 6 minutes after treatment applica-
tion and maintained it until surgical closure.
● Proportion of patients who achieved hemostasis at the
study suture line at 10 minutes after treatment appli-
cation and maintained it until surgical closure.
● Incidence of intraoperative rebleeding at the study
suture line after the achievement of hemostasis.
● Incidence of postoperative rebleeding at the study
suture line requiring surgical re-exploration.
Overall safety was assessed by monitoring adverse
vents (AEs), including surgical site infections (SSIs) and
raft occlusions, laboratory values, vital signs, and concom-
tant medications.We defined an AE as any unfavorable and
nintended sign (including an abnormal laboratory find-
ng), symptom, or disease temporally associated with study
reatment, regardless of the presumed causality between
he event and treatment. SSIs were graded according to the
zilagyi classification system.23 Graft occlusions were de-
ermined clinically and defined as absence of blood flow
hrough the graft.
Patients. Upon provision of informed consent, all
ale and female patients scheduled for arterio-arterial by-
asses or AV shunts with ePTFE grafts were eligible for
nclusion in the study. Only patients with moderate or
evere anastomotic suture-hole bleeding that could not be
ontrolled with additional suturing were randomized to
ne of two treatment groups: FS or control.
Key exclusion criteria were other vascular procedures
lanned for the same surgical session, pregnant or lactating
omen, congenital coagulation disorders, prior kidney
ransplantation, heparin-induced thrombocytopenia, hy-
ersensitivity to aprotinin or other components of FS,
ypersensitivity to heparin, severe congenital or acquired
mmunodeficiency, prior radiation therapy to the operating
eld, and severe inflammation (ie, infection) at the operat-
ng field.
Investigational product. FS is a two-component bi-
logical fibrin sealant that mimics the final stage of the
lood coagulation cascade. The active ingredients of FS,
brinogen and thrombin (500 IU/mL), are manufactured
rom pooled human plasma that is obtained via a strict
creening program; two independent, virus inactivation/
eduction manufacturing steps (vapor heat treatment and
olvent/detergent treatment) further increase its viral
afety margin.20 Upon mixing of the two components,
oluble fibrinogen is transformed into a fibrin matrix that
dheres to the wound surface and achieves hemostasis and
ealing/gluing of tissues. During the course of wound
ealing, the solidified FS is slowly lysed and completely
esorbed within 10 to 15 days.24
Surgical procedure. The ePTFE graft placement was
erformed according to hospital standards. To avoid bias,
tudy-related surgical procedures were standardized to the
xtent possible across treatment groups.
Before initial clamping, patients who had arterio-
rterial bypass received 100 IU 10% heparin per kg body
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July 2012136 Saha et alweight, and patients who had AV shunts received 50 IU
10% heparin per kg body weight. Additional doses of
heparin were administered at the discretion of the investi-
gator. Heparin was reversed, if necessary, with protamine
after the primary end point assessment. Sutures and needles
were standardized for the graft anastomoses. For arterio-
arterial anastomoses, 5-0 Prolene sutures and C-1 needles
(Ethicon) were used. For AV shunts, 6-0 Prolene sutures
and RB-2 needles were used.
After completion of anastomotic suturing, cross
clamps were opened to determine if eligible suture-line
bleeding that could not be controlled with additional
suturing was present. If present, randomization was per-
formed, as stratified by bleeding severity. Bleeding was
defined as moderate if it affected25% of the suture line,
consisted of at least five suture-line bleeds, or consisted
of one pulsatile suture-line bleed. Bleeding was consid-
ered severe if it covered 50% of the suture line, con-
sisted of at least 10 suture-line bleeds, consisted of 1
pulsatile suture-line bleed, or consisted of at least one
spurting (ie, continuous) suture-line bleed. Upon com-
pletion of the bleeding assessment, vessels were rec-
lamped and randomization occurred.
In the FS group, a thin, continuous film of FS was
applied with a blunt application needle to the study suture
line, covering both the native vessel and ePTFE graft;
arterial flow was re-established after 2 minutes of polymer-
ization or setting of FS. In the control group, dry gauze
pads were positioned to completely cover the study suture
line; arterial flow was re-established immediately after
gauze pads were positioned and manual compression was
applied. The study suture line was inspected for bleeding at
4, 6, and 10 minutes after the start of application of FS or
positioning of gauze pads. In the control group, gauze pads
were momentarily lifted for inspection of the study suture
line. During the observation period, additional hemostatic
treatments on the study suture line were used only in cases
of severe bleeding that jeopardized subject safety. The
choice of alternative treatments was at the discretion of the
investigator; however, in the FS group, no fibrin sealant
other than FS was to be used, and in the control group,
neither FS nor any other fibrin sealant was to be used.
Furthermore, the perioperative administration of platelet
inhibitors was allowed in this study.
Treatment of bleeds at the nonstudy suture line was to
mirror that of bleeds at the study suture line; however, time
to hemostasis was not recorded.
Statistical methods. Sample size calculations were
based on the results of the previous phase 2 study.25 The
proportion of patients achieving hemostasis at 4 minutes
for FS was expected to be about 60%, and the rate for
control patients was expected to be about 35%. If the above
assumptions held true, a per-group sample size of 70 ran-
domized patients with valid assessments for the primary
end point was considered sufficient to show a difference
between treatment groups with a one-sided type one error
of 2.5% and a power of approximately 85%. 1The primary efficacy analysis was carried out on the
ntent-to-treat population (ie, all randomized patients), as
ell as on a subset who were administered platelet inhibi-
ors perioperatively (post hoc analysis); this subset included
atients who were under antiplatelet therapy preoperatively
nd either stopped therapy within 5 days before surgery
r continued therapy perioperatively. For comparison of
emostasis rates between treatment groups, the likelihood
atio 2 test was carried out with a 2.5% one-sided signifi-
ance level. In addition, the proportion of patients achiev-
ng hemostasis at 4 minutes in the treatment groups was
nalyzed using logistic regression, taking into account gen-
er, age, type of intervention, severity of bleeding, systolic
lood pressure, diastolic blood pressure, and heparin coat-
ng of the ePTFE graft, as well as platelet inhibitors in the
ost hoc analysis.
Proportions and corresponding 95% two-sided confi-
ence intervals (CIs) based on the likelihood ratio 2 test
ere calculated for each treatment group for the secondary
nd points. These end points were also analyzed using the
ikelihood ratio 2 test for proportions, comparing treat-
ent groups.
For the incidence of infections and graft occlusions,
roportions and corresponding 95% two-sided CIs based
n the likelihood ratio 2 test were calculated for each
reatment group. These variables were also analyzed using
he likelihood ratio 2 test for proportions, comparing
reatment groups.
ESULTS
A total of 140 patients between 33 and 90 years of age
ere treated in this study: 70 with FS and 70 with control.
he majority of patients underwent upper extremity AV
hunt placement (31/70 FS patients [44.3%] and 40/70
ontrol patients [57.1%]) and femoropopliteal arterio-
rterial bypass (24/70 FS patients [34.3%] and 17/70
ontrol patients [24.3%]; Table I). Demographic and base-
ine characteristics (Table II) and the number and type of
urgical procedures performed were comparable between
reatment groups.
The proportion of patients that achieved hemostasis at
he study suture line at 4 minutes and maintained it was
2.9% (44/70; 95% CI, 51.2-73.6) in the FS group and
1.4% (22/70; 95% CI, 21.4-42.8) in the control group
Table III). The one-sided P value from the likelihood
atio 2 test indicated a statistically significant difference at
he 2.5% one-sided level in the comparison of hemostasis
ates between treatment groups (P  .0001).
Logistic regression was performed on the primary end
oint adjusted for factors influencing hemostasis, including
latelet inhibitors. A statistically significant treatment effect
t the 5% two-sided level was observed in the odds ratio
OR) of achieving hemostasis at 4 minutes between treat-
ent groups (OR, 6.73; 95% CI, 2.65-17.11; P  .0001;
able IV). Statistically significant effects were also observed
or the type of intervention (OR, 0.25; 95% CI, 0.10-0.67;
 .0055) and severity of bleeding (OR, 2.59; 95% CI,
.16-5.81; P  .0209).
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Volume 56, Number 1 Saha et al 137Hemostasis rates at 4 minutes in patients on platelet
inhibitors, including aspirin, cilostazol, dipyridamole, dipy-
ridamole with aspirin, and clopidogrel, were comparable to
those in patients not on platelet inhibitors (Table V): 64.7%
(FS group) and 28.2% (control group) vs 61.1% (FS group)
and 35.5% (control group).
Hemostasis rates at 4minutes were higher formoderate
Table I. Surgical records
Surgical record Type/lo
Procedure
Arterio-arterial bypass Axillofemoral
Axillobifemor
Aortobifemor
Iliofemoral
Femorofemor
Iliopopliteal
Femoropoplit
Femorotibial
Arteriovenous dialysis access shunt Upper extrem
Lower extrem
ePTFE prosthesis type
Heparin coate
Not heparin c
Suture type
Running
Interrupted
Suture thickness
5.0
6.0
Needle type
C1
RB2
BV1
ePTFE, Expanded polytetrafluoroethylene; FS, fibrin sealant containing 500
Table II. Demographic and baseline characteristics
Parameter
FS group
n (%)
(n  70)
Control group
n (%)
(n  70)
Gender
Male 30 (42.9) 37 (52.9)
Female 40 (57.1) 33 (47.1)
Race
White 40 (57.1) 41 (58.6)
Black or African American 28 (40.0) 27 (38.6)
Asian 1 (1.4) 0 (0.0)
American Indian or Alaska
native 1 (1.4) 2 (2.9)
Ethnicity
Hispanic or Latino 4 (5.7) 6 (8.6)
Non-Hispanic or Latino 66 (94.3) 64 (91.4)
Age, years
Mean 62.5 66.3
SD 12.6 11.5
Median 63.5 68.0
Range 33-88 43-90
FS, Fibrin sealant containing 500 IU/mL thrombin and synthetic aprotinin.bleeders than severe bleeders in both treatment groups. memostasis rates were 75.9% (22/29; 95% CI, 58.5-88.8)
n the FS group vs 48.1% (13/27; 95% CI, 30.1-66.5) in
he control group for moderate bleeders, and 53.7% (22/
1; 95% CI, 38.5-68.4) in the FS group vs 20.9% (9/43;
5% CI, 10.7-34.6) in the control group for severe bleed-
rs. It is important to note that FS is not indicated for
reatment of massive and brisk arterial bleeding.
Differences were also observed in hemostasis rates at 6
nd 10minutes: 71.4% (50/70; 95%CI, 60.2-81.1) for the
S group vs 42.9% (30/70; 95% CI, 31.7-54.6) for the
ontrol group (P  .001), and 75.7% (53/70; 95% CI,
4.9-84.7) for the FS group vs 55.7% (39/70; 95% CI,
4.0-67.0) for the control group (P  .012), respectively.
The overall incidence of intraoperative rebleeding at
he study suture line was low (4/70 FS patients [5.7%] and
/70 control patients [1.4%]). Treatment of intraoperative
ebleeding included reapplication of FS, manual compres-
ion, additional sutures, thrombin-soaked Gelfoam, Surgi-
el, and other topical hemostatic agents such as Fibrillar
nd FloSeal. None of the treated patients had postoperative
ebleeding.
The evaluation of safety showed no remarkable differ-
nces between treatment groups in the occurrence of and
isk of experiencing all AEs (serious and non-serious),
erious adverse events (SAEs), and non-serious AEs during
r after treatment (Table VI).
None of the 26 SAEs that occurred in 20 of 70 FS
atients (28.6%) and none of the 23 SAEs in 18 of 70
atients (25.7%) were considered related to study treat-
FS group
n (%)
(n  70)
Control group
n (%)
(n  70)
2 (2.9) 1 (1.4)
1 (1.4) 0 (0.0)
5 (7.1) 5 (7.1)
0 (0.0) 1 (1.4)
4 (5.7) 2 (2.9)
2 (2.9) 0 (0.0)
24 (34.3) 17 (24.3)
bypass 1 (1.4) 2 (2.9)
31 (44.3) 40 (57.1)
0 (0.0) 2 (2.9)
33 (47.1) 33 (47.1)
37 (52.9) 37 (52.9)
70 (100.0) 69 (98.6)
0 (0.0) 1 (1.4)
38 (54.3) 28 (40.0)
32 (45.7) 42 (60.0)
38 (54.3) 28 (40.0)
31 (44.3) 41 (58.6)
1 (1.4) 1 (1.4)
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July 2012138 Saha et alOf the 125 non-serious AEs that occurred in 46 of 70
FS patients (65.7%), one was considered by the investi-
gator to be possibly related to FS; and of the 119
non-serious AEs that occurred in 40 of 70 control pa-
tients (57.1%), one was considered possibly related to
control. One FS patient underwent a femoropopliteal
bypass and experienced severe bleeding at the study
suture line. FS was applied, resulting in hemostasis at 6
minutes. During closure of the wound, the investigator
noticed an area of blood welling up and seeping from
under the application of FS at the study suture line. FS
Table III. Summary of hemostasis at 4 minutes after treat
Study group
Hemostasis
achieved at 4
minutesa
n (%) (n  70)
Additiona
treatmen
required t
achieve hemo
n (%) (n 
FS 47 (67.1) 13 (18.6
Control 22 (31.4) 28 (40.0
FS, Fibrin sealant containing 500 IU/mL thrombin and synthetic aprotinin
aIncludes patients who achieved hemostasis at 4 minutes but required addit
bPrimary efficacy end point.
Table IV. Logistic regression: factors influencing hemosta
Factor
FS vs control
Gender (male vs female)
Age, years
Type of intervention (arterio-arterial bypass vs arterioven
Severity of bleeding (moderate vs severe)
Systolic blood pressure, mm Hg
Diastolic blood pressure, mm Hg
Heparin coating of the ePTFE prosthesis (yes vs no)
Platelet inhibitors (yes vs no)b
CI,Confidence interval; ePTFE, expanded polytetrafluoroethylene; FS, fibrin
Platelet inhibitor yes, if start date of the respective medication was before s
surgery date) and (1) in case the stop date of medication is ongoing or (2) in
days are between stop date of medication and surgery date or (4) in case sto
aOdds ratios, CIs, and P values were estimated from the logistic model acco
bPlatelet inhibitors: aspirin, cilostazol, dipyridamole, dipyridamole with asp
Table V. Primary efficacy end point for patients on
antiplatelets
Platelet
inhibitors
FS group
n of n (%)
Control group
n of n (%)
Yes 22 of 34 (64.7) 11 of 39 (28.2)
No 22 of 36 (61.1) 11 of 31 (35.5)
FS, Fibrin sealant containing 500 IU/mL thrombin and synthetic aprotinin.
Platelet inhibitor yes, if start date of the respective medication was before
surgery date (for an unknown start date, it is assumed that the start date was
before surgery date) and (1) in case the stop date of medication is ongoing
or (2) in case the stop date of medication is after surgery date or (3) in case
less than 5 full days are between stop date of medication and surgery date or
(4) in case stop date of medication is unknown and not ongoing.was removed, additional sutures were placed, and 2 mL pf FS as well as Gelfoam and thrombin were applied to
chieve hemostasis. The event was mild in severity and
esolved the same day. One control patient underwent a
emorofemoral bypass and experienced severe bleeding
t the study suture line. Manual compression and Surgi-
el were applied, resulting in hemostasis at 10 minutes.
n postoperative day 15, the patient experienced a 3-cm
ight groin hematoma. The event was moderate in sever-
ty and resolved after 9 days.
In the FS group, five of 70 patients (7.1%) experienced
raft occlusions and seven of 70 patients (10.0%) experi-
nced SSIs. Of the seven patients with SSIs, five patients
7.1%) experienced grade I (only dermis affected) infec-
ions, whereas two patients (2.9%) experienced grade II
infection invades subcutaneous region but not the arterial
mplant); no arterial implant infections occurred (Table
II). None of the SSIs or graft occlusions that occurred
uring the study was considered related to FS.
In the control group, eight of 70 patients (11.4%) expe-
ienced graft occlusions and five of 70 patients (7.1%) experi-
nced SSIs. In the control group, three patients (4.3%) expe-
ienced grade I infections; one patient (1.4%) experienced a
rade II infection; and one patient (1.4%) experienced a grade
II infection (arterial implant infected; Table VIII).
Suspected anaphylactic or anaphylactoid reactions to
S and virus transmission were not reported in any of the
t
Intraoperative
rebleeding after
primary hemostasis
n (%) (n  70)
Hemostasis achieved
at 4 minutes and
maintained until
surgical closureb
n (%) (n  70)
4 (5.7) 44 (62.9)
1 (1.4) 22 (31.4)
reatment and/or experienced intraoperative rebleeding.
t 4 minutes after treatment
OR 95% CI for OR P valuea
6.73 2.65-17.11 .0001
0.60 0.26-1.38 .2257
0.99 0.95-1.03 .5276
unt) 0.25 0.10-0.67 .0055
2.59 1.16-5.81 .0209
0.98 0.96-1.00 .1208
1.04 1.00-1.08 .0662
0.90 0.40-2.02 .8045
1.50 0.65-3.48 .3465
t containing 500 IU/mL thrombin and synthetic aprotinin;OR, odds ratio.
date (for an unknown start date, it is assumed that the start date was before
he stop date of medication is after surgery date or (3) in case less than 5 full
e of medication is unknown and not ongoing.
g for the effects mentioned in the “Factor” column.
d clopidogrel.men
l
t
o
stasis
70)
)
)
.sis a
ous sh
sealan
urgery
case t
p datatients treated with FS.
g
l
s
a
g
6
w
s
f
b
c
p
b
l
e
a
v
p
a
0 IU
nstruc
JOURNAL OF VASCULAR SURGERY
Volume 56, Number 1 Saha et al 139DISCUSSION
The ideal hemostatic agent for suture-line bleeding
during vascular reconstructive surgery using ePTFE grafts
should be both effective and fast-acting because perioper-
ative blood loss poses significant health risks and can
lengthen operating times and consequently increase costs.
Clinical data on hemostatic agents in this type of applica-
tion are limited, and, therefore, the ideal hemostatic agent
has not yet been established.26
The main objectives of this study were to investigate
whether the use of FS is beneficial for the treatment of
anastomotic suture-hole bleeds that are not amenable to
additional sutures, including those further complicated by
concomitant platelet inhibitors.
The hemostatic advantages of FS over manual com-
pression, as observed in the previous phase 2 study,25 were
confirmed in the present study. A statistically significant
difference was observed between treatment groups in the
proportion of patients that achieved hemostasis at the study
suture line at 4 minutes and maintained it until surgical
Table VI. Patients with AEs that occurred during/after tr
Study group
All AEs FS
Control
SAEs FS
Control
Non-serious AEs FS
Control
AEs, Adverse events; CI, confidence interval; FS, fibrin sealant containing 50
SAEs, serious adverse events.
Table VII. SSIs and graft occlusions in FS patients
Reported term
SSIs
Postoperative surgical site infection with Morganella m
Methicillin-sensitive Staphylococcus aureus at right groin
surgical site
Superficial wound infection
Superficial (dermal) cellulitis left groin surgical site
Cellulitis to right groin incision
Infection at left popliteal incision
Wound infection postoperative
Graft occlusions
Clotted left AV graft
Loop graft thrombosis-left arm
Loop graft thrombosis-left arm
Occluded graft
Failed right forearm straight AV graft
Failed right forearm straight AV graft
Stricture compression of vein left arm
Stricture compression of artery left arm
AV, Arteriovenous; FS, fibrin sealant containing 500 IU/mL thrombin and
aSzilagyi DE, Smith RF, Elliott JP, Vrandecic MP. Infection in arterial recoclosure: 62.9% in the FS group vs 31.4% in the control proup (P  .0001). This difference is confirmed by the
ogistic regression analysis, which indicated a statistically
ignificant treatment effect (P  .0001) in the OR of
chieving hemostasis at 4 minutes between the treatment
roups. The odds of achieving hemostasis at 4 minutes was
.30 times higher for FS patients than control patients,
hich is consistent with the results of a number of clinical
tudies comparing fibrin sealants to manual compression
or hemostasis in vascular surgery.6,7,11 When analyzed
y bleeding severity, the hemostatic advantage of FS over
ontrol at 4 minutes was similar (27.8% absolute im-
rovement for moderate bleeding vs 32.8% for severe
leeding).
The primary efficacy analysis should be interpreted in
ight of the following challenges in the study design: the
xclusion of all mild bleedings from the analysis, only one
pplication of FS at the study suture line, only ePTFE
ascular grafts, heparinization and the administration of
rotamine for reversal of heparin after primary end point
ssessment, inclusion of perioperative administration of
ent
(%)
70)
FS vs control
RR 95% CI of RR
8.6%) 1.115 0.875-1.420
1.4%) NA NA
8.6%) 1.108 0.649 to 1.892
5.7%) NA NA
5.7%) 1.148 0.884 to 1.492
7.1%) NA NA
/mL thrombin and synthetic aprotinin; NA, not applicable; RR, risk ratio;
Relationship to
treatment with FS SSI gradea
ii Not related II
Not related II
Not related I
Not related I
Not related I
Not related I
Not related I
Not related
Not related
Not related
Not related
Not related
Not related
Not related
Not related
etic aprotinin; SSIs, surgical site infections.
tion with synthetic grafts. Ann Surg 1972;176:321-33.eatm
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July 2012140 Saha et alvention of bleeding-related complications27,28), and inclu-
sion of various types of arterial bypasses. Recently released
evidence-based guidelines and literature suggest that the
practice of withdrawing platelet inhibitors 5 to 10 days
before intermediate-risk to high-risk surgical procedures
may increase thrombotic risk.29-31 It is important to note
that the hemostatic success rate at 4minutes in the subset of
patients on platelet inhibitors was approximately two times
higher in the FS group than the control group, which is
similar to the trend observed in patients not on platelet
inhibitors and thereby confirms the effectiveness of FS
independent of the patients’ coagulation status.
In all, the significant difference observed for the pri-
mary end point and the statistically significant treatment
effect demonstrate that FS is superior to manual compres-
sion for hemostasis in patients receiving peripheral vascular
ePTFE grafts, including arterio-arterial bypasses and AV
shunts.
In patients undergoing arterio-arterial bypass grafting,
as well as AV shunting, generally, the aim is to create a graft
that is durable, to have minimal risk of infection, and to
require few interventions to maintain patency. The results
of this phase 3 study validate the safety profile of FS in
vascular surgery. None of the SAEs that occurred in this
study was considered related to FS. The AEs most fre-
quently reported in both treatment groups are expected in
patients undergoing vascular surgery without the use of
fibrin sealant.32,33 Several factors may influence the rate of
graft occlusions and infections, including patients’ under-
lying disease and their progression, comorbidities, surgical
technique, history of previous graft placement, graft mate-
rials used, anatomic features, antibiotic prophylaxis, and
wound management.23,34,35 The occurrence of graft oc-
clusions and SSIs was similar between treatment groups
Table VIII. SSIs and graft occlusions in control patients
Reported term
SSIs
Right lower extremity cellulitis along surgical site
Right surgical site groin infection
Surgical wound/incision infection in the right groin
Left upper arm graft infection due to MRSA sepsis
Cellulitis at right groin incision
Right groin cellulitis at incision site
Graft occlusions
Thrombosed AV graft
Thrombosis of AV graft
Occluded right AV graft
Graft thrombosis
Occluded left femoropopliteal bypass graft
Graft occlusion secondary to thrombosis
Graft occlusion
Graft occlusion
Graft occlusion
AV, Arteriovenous; MRSA, methicillin-resistant Staphylococcus aureus; SSIs,
aSzilagyi DE, Smith RF, Elliott JP, Vrandecic MP. Infection in arterial recoand consistent with published literature, confirming that Oound infections are a common cause of morbidity in open
urgery for vascular disease.36
No evidence to support concerns relating to
ypersensitivity/allergic reactions and suspected viral
ransmission as a result of FS use was found in this study
r other published reports on fibrin sealants as hemo-
tatic agents.1,37-39
Overall, there was no apparent frequency of certain
ypes of AEs and no differences in the risk of experiencing
Es between treatment groups.
ONCLUSIONS
The findings from this study demonstrate that FS is safe
nd its efficacy is superior to manual compression for he-
ostasis in patients with peripheral vascular ePTFE grafts.
he data also suggest that FS promotes hemostasis inde-
endently of the patient’s own coagulation system, as
hown in a representative population of patients with vas-
ular disease under single- or dual-antiplatelet therapies.
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